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ABSTRACT
Aims: To investigate the association between overweight/obesity and fatty liver index (FLI) on
the odds of incident prediabetes/type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
in 2020 participants after 10 years follow up.
Methods: At baseline (in 2001) 2020 participants, males and females, aged 24–39 years, were
stratified according to body mass index (BMI), normal weight (<25 kg/m2), overweight
(25–<30 kg/m2), or obese (30 kg/m2) and FLI (as high FLI 60 or low FLI <60). We examined
the incidence of prediabetes/type 2 diabetes and NAFLD (ultrasound assessed) over 10 years to
2011 to determine the relative impact of FLI and BMI.
Results: 514 and 52 individuals developed prediabetes and type 2 diabetes during follow-up.
Such individuals were older, with higher BMI, serum glucose, insulin, alanine aminotransferase
(ALT) and triglyceride (TG) concentrations than those who did not develop prediabetes or type
2 diabetes (n¼ 1454). The additional presence of high FLI significantly increased the risk of
developing prediabetes and type 2 diabetes above the risk of being overweight/obese.
Compared with normal weight, low FLI participants, the odds of prediabetes were 2-fold
higher and the odds of type 2 diabetes were 9–10-fold higher respectively in the overweight/
obese, high FLI group. No difference was observed between normal weight, low FLI and over-
weight/obese and low FLI groups.
Conclusions: An increased FLI significantly increases the odds of incident prediabetes, type 2
diabetes and NAFLD in individuals with overweight/obese highlighting the contributory role of
liver fat accumulation in the pathophysiology of prediabetes/type 2 diabetes.
KEY MESSAGES
 Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), prediabetes and type
2 diabetes.
 Additionally, NAFLD is more prevalent in people with prediabetes and type 2 diabetes when
compared to age- and BMI-matched individuals.
 The presence of a raised fatty liver index (FLI) confers a significantly increased risk of devel-
oping prediabetes, type 2 diabetes and NAFLD above that conferred by being over-
weight/obese.
 The degree of elevation of FLI can risk stratify for incident prediabetes and type 2 diabetes in
people with obesity.
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Introduction
Obesity is the major risk factor for the development of
type 2 diabetes with the risk of type 2 diabetes
increasing exponentially with body mass index (BMI), a
relationship particularly more pronounced in females
[1,2]. Additionally, obesity also represents a major risk
factor for development of non-alcoholic fatty liver dis-
ease (NAFLD) [3]. There is a clear bidirectional relation-
ship between NAFLD and type 2 diabetes with a
higher prevalence of NAFLD (both liver steatosis and
fibrosis) in type 2 diabetes compared with age- and
BMI-matched individuals [4,5] while the prevalence of
type 2 diabetes among those with NAFLD and non-
alcoholic steatohepatitis (NASH) is estimated to be
22.5% and 43.6%, respectively [6].
Marchesini et al. first suggested NAFLD represented
the hepatic manifestation of the metabolic syndrome
based on metabolic studies demonstrating hepatic
and peripheral insulin resistance in 30 people with
biopsy-proven NAFLD, compared with 10 healthy con-
trols and 10 people with type 2 diabetes [7]. However,
the contribution of fatty liver to incident type 2 dia-
betes was first recognized in Pima Indians when high
ALT (a biochemical surrogate of NAFLD), associated
with increased hepatic glucose output and hepatic
insulin resistance, was found to predict development
of type 2 diabetes [8]. In the West of Scotland
Coronary Prevention Study (WOSCOPS), serum ALT,
but not serum aspartate transaminase (AST) levels,
increased progressively as the number of metabolic
syndrome components increased [9]. The association
of serum ALT with metabolic syndrome/incident type
2 diabetes were reproduced in other studies [9–11].
Remarkably, even ALT levels within the upper normal
range were associated with higher rates of incident
type 2 diabetes [9] while normal serum ALT concentra-
tions do not exclude the presence of NAFLD [4] lead-
ing to proposals to revise the normal reference range
of serum ALT concentrations [12]. Serum ALT concen-
tration, even with a normal range between 6 and
40 IU/L, has a linear dose-response relationship with
risk of metabolic syndrome [13]. A systematic review
of all the studies that have assessed the association
between ALT level and type 2 diabetes, demonstrated
that per 5 IU/L increase in serum ALT, there was a 16%
increased risk of incident type 2 diabetes [10].
The strongest evidence of the association between
NAFLD and incident type 2 diabetes comes from a
meta-analysis of 19 observational cohort studies
involving 296,439 people of whom 30.1% had NAFLD,
diagnosed by imaging studies [14]. Over a median fol-
low up of 5 years and 16,000 cases of incident type 2
diabetes, NAFLD at baseline associated with a more
than doubling of the hazard ratio (HR) of incident
type 2 diabetes. Furthermore, the incidence of type 2
diabetes increased with the severity of steatosis
(graded by ultrasonography) and in those with
advanced fibrosis (higher NAFLD fibrosis scores)
at baseline.
One issue that remains contentious is the relative
degree by which obesity and NAFLD independently
contribute to type 2 diabetes. A recent meta-analysis
of participants classified as having metabolically
healthy obesity (MHO) vs. metabolically unhealthy
obesity (MUO) found the risk for incident type 2 dia-
betes was approximately 4- and 9-fold higher com-
pared with those classified as MHO and normal
weight [15], suggesting type 2 diabetes is influenced
by the metabolic sequelae of excess weight rather
than simply by obesity per se.
Previously, Bedogni et al. used data from the
Dionysos Nutrition & Liver Study to develop a simple
algorithm (based on BMI, waist circumference, serum
triglycerides (TGs) and gamma-glutamyl transferase
[GGT]), for the prediction of fatty liver/hepatic steatosis
(as detected by ultrasonography) in the general popu-
lation. The algorithm, referred to as the fatty liver index
(FLI), had a receiver operating characteristics area
under the curve (ROC-AUC) of 0.85 (95% CI 0.81–0.88).
Using FLI <30 it can be used to rule out hepatic stea-
tosis (sensitivity of 87%) or to rule in hepatic steatosis
when FLI 60 (specificity of 86%) for purposes of
screening, identifying individuals for intensified lifestyle
counselling or in epidemiologic studies [16]. We subse-
quently validated the FLI as a measure of hepatic stea-
tosis with liver fat determined quantitatively by proton
magnetic resonance spectroscopy (1H-MRS) [17].
Significantly, the close relationship of NAFLD with insu-
lin resistance and its cardiometabolic burden since
childhood is important to consider as the early seeds of
disease are planted much earlier in life [18–20].
Therefore, we aimed to examine the relationship
between baseline FLI, a non-invasive steatosis score,
and overweight/obesity status on the incidence of pre-
diabetes/type 2 diabetes and NAFLD in a cohort of
2020 young adults over a follow up of 10 years.
Methods
Participants and study design
The Cardiovascular Risk in Young Finns Study is an
ongoing multicentre study examining precursors of
atherosclerosis in Finnish children and adolescents.
The first cross-sectional survey was conducted in 1980
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when 3596 children and adolescents (age 3–18 years)
participated [21]. Thereafter, several follow-up studies
have been performed with the most recent concluding
in 2011.
The sample for this analysis included those partici-
pants who had ALT and GGT levels measured from
the 2001 follow-up study (age 24–39 years) and had
participated in the latest follow-up in 2011 (age
34–49 years). A total of 2020, males and females, were
included in this analysis (Figure 1). Subjects with type
1 diabetes mellitus (n¼ 12), type 2 diabetes at base-
line (n¼ 9) and those female participants who were
pregnant at either time point (n¼ 50) were excluded.
Participants gave written informed consent and the
study was approved by local ethics committees.
Body composition, blood pressure and questionnaires:
Height, weight and waist circumferences were meas-
ured. BMI was calculated using the formula: weight
[kg]/(height [m])2. Blood pressure was measured using
a random zero sphygmomanometer. The average of
three measurements was used in the analysis.
Smoking habits and alcohol intake was inquired with
the use of questionnaires. Subjects were asked to
report their alcohol consumption of cans or bottles (1/
3 l) of beer, glasses (12 cl) of wine and shots (4 cl) of
strong alcohol per week. The values of different bever-
ages consumed during the week allowed us to deter-
mine total alcohol intake in grams per day.
Biomarker measurements: Venous blood samples
were collected after a 12-h fast from the right
antecubital vein. Determination of serum glucose and
TG concentrations were determined enzymatically
(Olympus System Reagent; Olympus System Reagent;
Olympus Diagnostica GmbH, Hamburg, Germany) in a
clinical analyser (AU400, Olympus, Tokyo, Japan).
Serum ALT and GGT activities were measured enzy-
matically on an automatic analyser (AU400, Olympus,
Tokyo, Japan). The mean inter-assay coefficient of vari-
ation was 3.7% for ALT and 2.1% for GGT. Serum insu-
lin concentration was determined by a microparticle
enzyme immunoassay (IMx insulin reagent, Abbott
Diagnostics, Abbott Park, IL) on an IMx instrument
(Abbott), with the result used to calculate HOMA-
IR [22].
Participants were classified as having prediabetes if
they had a glucose 5.6–6.9mmol/L (100–125mg/dL) or
had a glycated haemoglobin (A1C) level of 5.7–6.4%
(42–47mmol/mol) and reported not receiving oral
hypoglycaemic agents and/or insulin injections and
did not have type 1 or 2 diabetes; or reported a his-
tory of physician-diagnosed type 2 diabetes.
Participants were classified as having type 2 diabetes
if they had a fasting plasma glucose 7.0mmol/L
(126mg/dL), had a glycated haemoglobin (A1C) level
of 6.5% (48mmol/mol), reported receiving oral hypo-
glycaemic agents and/or insulin injections and did not
have type 1 diabetes; or reported a history of phys-
ician-diagnosed type 2 diabetes.
Definition of the FLI: It was determined using an
algorithm introduced by Bedogni et al. as follows:
ðe0:953loge ðTGsÞþ0:139BMIþ0:718loge GGTð Þþ0:053waist circumference15:745Þ=ð1
þ e0:953loge ðTGsÞþ0:139BMIþ0:718loge GGTð Þþ0:053waist circumference15:745Þ  100 16ð Þ:
Figure 1. Schematic of study design.
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Reference groups: Participants were classified further
into groups according to their BMI and FLI status at
both time points (2001 and 2011). FLI was categorized
as low, <60 (FLI) or high, 60 (FLIþ). We performed
sensitivity analyses using cut-offs for high FLI as
85th, 80th and 75th percentiles for FLI-value.
Results were essentially similar as in the main analyses.
These results are presented in the online supplement
(Supplementary Table 1). We undertook separate anal-
yses determining the impact of being either over-
weight (BMI 25 kg/m2) or obese (BMI 30 kg/m2)
(BMIþ) compared with BMI <25 kg/m2 or BMI <30 kg/
m2 (BMI), respectively. At this time point (2001), the
population studied were younger, leaner and relatively
healthy. Thus, the reference group was participants
with low BMI (BMI) and low FLI (FLI).
Ultrasound imaging: Ultrasound studies were per-
formed in 2011 (ultrasound was not performed in
2001) by trained physicians and sonographers follow-
ing standardized protocols and used to determine the
presence or absence of NAFLD, based on hepatic stea-
tosis [23]. Examinations were performed with Acuson
Sequioia 512 ultrasound (Acuson, Mountain View, CA).
Liver fat was scanned using 4.0-Mhz adult abdominal
transducers. A trained sonographer graded the liver
fat status from the ultrasonographical images using
five widely accepted criteria for fatty liver [24]. The
liver-to-kidney contrast, parenchymal brightness, deep
beam attenuation, bright vessel walls and visibility of
the neck of the gallbladder. For statistical analyses, we
used a binary outcome variable (normal vs. fatty liver)
based on the sonographer’s clinical judgement of the
image data.
Statistical methods: Values for FLI, serum ALT, GGT
and TG, were loge-transformed to correct for skew-
ness. Participant characteristics were compared using
t-tests and chi-square tests as appropriate. Linear
regression adjusted for age and sex was used to
assess associations between risk factors and future
outcome groups (no pre-diabetes or type 2 diabetes,
pre-diabetes and type 2 diabetes). To assess the inde-
pendent associations between risk factors and type 2
diabetes, we performed stepwise multivariable regres-
sion modelling using SAS stepwise selection. In initial
models, all variables in univariable model were
included. Next, variables were removed from the
model one by one until all the variables remaining in
the model were statistically significant (p< .05). At
each step, the variable showing the smallest contribu-
tion to the model was removed. Age-and sex-adjusted
logistic regression model was used to calculate odds
ratios and 95% confidence intervals (CIs). Statistical
analyses were performed with SAS version 9.4 (SAS
Institute Inc., Cary, NC). Statistical significance was
inferred as a p value of less than .05.
Results
Participant characteristics: Participant characteristics for
all participants are shown in Table 1 stratified by sex
and by pre-diabetes/type 2 diabetes status. Significant
differences were observed in BMI and in serum glu-
cose, liver enzyme concentrations (serum ALT and
GGT) and TG concentrations between sexes (p always
< .0001). Of the original cohort of 2020 individuals,
514 participants (201 males, 304 females) developed
prediabetes and 52 participants (28 males, 24 females)
developed incident type 2 diabetes in 2011. As
expected, the risk of type 2 diabetes varied according
to BMI for each sex (Supplementary Table 2). The
baseline clinical characteristics (in 2001) for those who
did not develop incident prediabetes/type 2 diabetes
and for those who developed either prediabetes or
type 2 diabetes were compared. Individuals who
Table 1. Participant characteristics at baseline (2001) according to prediabetes or type 2 diabetes (T2D) status at follow-
up (2011).
Male Female No incident prediabetes/T2D Incident prediabetes Incident T2D p Value for trend
N 923 (44%) 1097 (56%) 1454 514 52 –
Age (years) 31.7 (5.0) 31.9 (4.9) 31.6 (5.0) 32.5 (4.9) 34.1 (4.6) .011
BMI (kg/m2) 25.7 (4.0) 24.4 (4.6) 24.5 (4.2) 25.8 (4.3) 31.0 (6.2) <.0001
Waist circumference
(cm)
89.9 (10.7) 79.1 (11.2) 83.6 (12.0) 87.1 (11.7) 98.0 (14.7) <.0001
ALT (mmol/L) 14.5 (10.3) 8.5 (5.3) 10.5 (8.3) 12.3 (9.2) 17.7 (10.6) <.0001
GGT (U/L) 32.5 (26.2) 18.0 (12.9) 23.1 (21.0) 26.4 (19.1) 38.7 (24.0) <.0001
TG (mmol/L) 1.53 (1.02) 1.17 (0.70) 1.28 (0.87) 1.42 (1.05) 1.78 (0.86) <.0001
FLI (units) 40.1 (5.1–92.7) 19.7 (2.3–76.2) 28.1 (2.8–87.6) 34.9 (3.3–90.2) 64.2 (4.8–98.1) <.0001
Glucose (mmol/L) 5.18 (0.58) 4.88 (0.45) 5.0 (0.53) 5.02 (0.32) 5.53 (0.48) <.0001
Insulin (mIU/L) 7.6 (5.0) 7.7 (5.6) 7.2 (4.76) 7.6 (4.8) 14.4 (6.5) <.0001
HOMA-IR (units) 0.09 (0.07) 0.10 (0.09) 0.09 (0.06) 0.09 (0.06) 0.20 (0.10) <.0001
ALT: alanine aminotransferase; BMI: body mass index; FLI: fatty liver index (95% confidence intervals); GGT: gamma-glutamyl transferase; HOMA-IR:
homeostatic model assessment of insulin resistance; TG: triglycerides.
p Value for trend according to prediabetes or T2D status at follow-up using linear regression adjusted for age and sex.
The HOMA-IR was calculated by multiplying fasting Insulin (U/mL) by fasting glucose (mmol/L) and dividing by 22.5.
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developed either prediabetes or type 2 diabetes were
older, with higher BMI, waist circumference, serum
glucose, insulin and HOMA-IR, liver enzyme concentra-
tions (ALT and GGT), TG concentrations and FLI values.
Participants free from incident pre-diabetes and type 2
diabetes also had lower glucose, insulin and HOMA-IR
compared to those who did develop type 2 diabetes
but not compared to those who developed prediabe-
tes. Results were similar when those excluded were
included in the main analysis.
Longitudinal associations between risk factors
and incident NAFLD and type 2 diabetes
When we examined the association between risk fac-
tors in 2001 and risk of either NAFLD or type 2 dia-
betes in 2011, we found that all risk factors including
adiposity markers (waist circumference and BMI) and
FLI were associated with ultrasound-diagnosed NAFLD
and type 2 diabetes in 10-year follow-up (Table 2).
Next, we constructed a multivariable stepwise regres-
sion model assessing the independent relation
between baseline risk factors and future NAFLD and
type 2 diabetes (Table 3). Age, sex and alcohol con-
sumption were forced into the models. The model
included FLI, ALT, GGT, waist circumference, BMI
and TG.
Incident NAFLD (Table 3(a)): FLI remained associated
with increased risk for NAFLD when treated as con-
tinuous variables and dichotomous variables (OR [95%
CI], 3.09 [2.53–3.78] and 1.73 [1.18–2.53]); similarly, ALT
remained associated with increased risk for NAFLD
when treated as continuous variables and dichotom-
ous variables (OR [95% CI], 1.50 [1.12–2.02] and 1.63
[1.13–2.53], respectively. High BMI and high TG were
additionally associated with future NAFLD when
Table 2. Independent association between risk factors in 2001 and non-alcoholic fatty liver disease (NAFLD)
and type 2 diabetes (T2D) in 2011.
NAFLD T2D
Risk factor OR (95% CI) p Value OR (95% CI) p Value
Waist circumference (cm) 1.09 (1.05–1.13) <.0001 1.17 (1.04–1.32) .01
BMI 1.23 (1.12–1.34) <.0001 1.42 (1.09–1.74) .009
(log)FLI 3.50 (2.16–5.67) <.0001 1.06 (1.01–1.11) .017
(log)ALT 6.26 (2.67–14.7) <.0001 10.2 (1.04–100.2) .05
(log)GGT 3.86 (1.80–8.26) <.0001 3.05 (0.31–39.3) .31
(log)TG 3.15 (1.62–6.15) <.0001 0.70 (0.06–9.06) .78
All models include adjustment for age and sex.Odds ratios and their 95% confidence intervals (OR 95% CI) are for NAFLD and T2D for a one unit increase in the baseline
risk factor.
Table 3. Multivariable stepwise logistic regression model assessing the association between risk factors in
2001 and a) NAFLD and b) Type 2 diabetes (T2D) in 2011.
a)
Continuous NAFLD Dichotomous NAFLD
risk factor OR (95% CI) p Value risk factor OR (95% CI) p Value
(log)FLI 3.09 (2.53–3.78) <.0001 High FLI 1.73 (1.18–2.53) .005
(log)ALT 1.50 (1.12–2.02) .0072 High ALT 1.63 (1.13–2.53) .009
(log)GGT   High GGT 1.54 (1.06–2.26) .026
waist   High waist  
BMI   High BMI 2.30 (1.68–3.14) <.0001
(log)TG   High TG 2.26 (1.59–3.21) <.0001
b)
Continuous T2D Dichotomous T2D
risk factor b± SE p Value risk factor b ±SE p Value
(log)FLI 3.84 (2.31–6.38) <.0001 High FLI 2.67 (1.13–6.27) .0026
(log)ALT 2.25 (1.28–3.98) .005 High ALT  
(log)GGT   High GGT 2.86 (1.49–5.46) .0015
waist   High waist 3.48 (1.54–7.58) .0017
BMI   High BMI  
(log)TG   High TG  
All models include adjustment for age, sex and alcohol consumption.
High FLI was determined as having index >¼ 60 units.
ALT, GGT and triglyceride were determined as  85 percentile.
High BMI  25 kg/m2, high waist  88 cm in women and 102cm in men.Odds ratios and their 95% confidence intervals (OR 95% CI) are for NAFLD and T2D for a one unit increase in the baseline
risk factor.Variable did not meet the .05 significance level for entry into the model.
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treated as dichotomous variable in a stepwise model.
Variables that did not meet the p .05 significance
level during the stepwise procedure and thus were
dropped from the model. Due to high multicollinearity
between risk factors the results should be interpreted
cautiously when included in the same model.
Incident type 2 diabetes (Table 3(b)): FLI remained
associated with increased risk for type 2 diabetes
when treated as continuous variables and dichotom-
ous variables (OR [95% CI] 3.84 [2.31–6.38] and 2.67
[1.13–6.27], high ALT remained associated with
increased risk for type 2 diabetes when treated as con-
tinuous variables (OR 2.25 [95% CI] [1.28–3.98]). Waist
circumference, BMI, GGT and TG did not meet the
p .05 significance level during the stepwise proced-
ure and thus were dropped from the model.
Prediction of prediabetes and type 2 diabetes
between different phenotypes assessing overweight/obes-
ity and FLI: Table 4 shows the odds ratio estimates (OR
95% CI) in predicting prediabetes between partici-
pants that were normal weight and low-FLI (BMI,
FLI) (reference group), participants that were normal
weight with high-FLI (BMI, FLIþ), overweight but
low-FLI (BMIþ, FLI) and participants with over-
weight/obesity and had a high-FLI (BMIþ, FLIþ). In
normal weight participants, a higher FLI did not sig-
nificantly increase the risk of prediabetes vs. lower FLI
participants; however, a higher FLI in participants with
overweight and obesity was associated with a signifi-
cantly higher risk of prediabetes than those with a
lower FLI (OR 2.12 [1.57–2.85] and 1.87 [1.28–2.72]).
Table 5 shows the odds ratio estimates (OR 95% CI)
in predicting type 2 diabetes between participants
that were normal weight and low-FLI (BMI, FLI)
(reference group), participants with overweight/obesity
but low-FLI (BMIþ, FLI) and participants with over-
weight/obesity and had a high-FLI (BMIþ, FLIþ). Not
enough participants with normal weight but high-FLI
(BMI, FLIþ) were observed to perform analysis.
Normal weight participants with a higher FLI did not
increase the risk of developing type 2 diabetes
10 years later. However, a higher FLI in participants
with overweight/obesity was associated with a signifi-
cantly higher risk of type 2 diabetes than those with a
lower FLI (OR 10.3 [5.69–18.4] and 8.94 [4.86–16.5]).
Discussion
This study, in a large cohort of 2020 young Finnish
men and women, examined the interaction between
FLI and being overweight or obese in the subsequent
development (over 10 years) of prediabetes, type 2
diabetes and NAFLD. In participants with overweight
or obesity, higher FLI values increased the risk of pre-
diabetes more than 3-fold compared with similar BMI-
matched individuals with lower FLI; more strikingly
higher FLI increased the risk of type 2 diabetes by
more than 10- and 15-fold in participants with over-
weight or obesity compared with similar BMI-matched
individuals with lower FLI. This highlights a stratifica-
tion of risk according to weight category and pres-
ence/absence of NAFLD (indicative of liver fat
accumulation) for incident prediabetes and type
2 diabetes.
Other studies have explored an association
between NAFLD and type 2 diabetes based on bio-
chemical surrogates of NAFLD or through imaging
studies, e.g. abdominal ultrasonography. However, we
Table 4. Odds ratio (OR) and 95% confidence intervals (CI)
for incident prediabetes according to body mass index (BMI)
and fatty liver index (FLI) status (FLIþwhen >¼ 60 units,
FLIwhen < 60 units) at baseline a) BMI < 25 kg/m2 and b)
BMI < 30 kg/m2.
a)
Frequency
(n¼ 2020) Percent OR (95% CI) (p Value)
(BMI, FLI) 1300/335 64.3 Reference Reference
(BMI, FLIþ) 10/4 0.5 2.06 (0.50–8.41) .31
(BMIþ, FLI) 438/162 21.7 1.68 (1.33–2.14) <.0001
(BMIþ, FLIþ) 272/124 13.5 2.12 (1.57–2.85) <.0001
b)
Frequency
(n¼ 2020) Percent OR (95% CI) (p Value)
(BMI, FLI) 1703/479 84.3 Reference Reference
(BMI, FLIþ) 121/64 6.0 1.87 (1.26–2.77) <.0001
(BMIþ, FLI) 35/18 1.7 4.47 (2.17–9.23) <.0001
(BMIþ, FLIþ) 161/64 8.0 1.87 (1.28–2.72) <.0001
Table 5. Odds ratio (OR) and 95% confidence intervals (CI)
for incident T2D according to body mass index (BMI) and
fatty liver index (FLI) status (FLIþwhen >¼ 60 units,
FLIwhen < 60 units) at baseline A) BMI < 25 kg/m2 and B)
BMI < 30 kg/m2.
A)
Frequency (n¼ 2020) Percent OR (95 % CI) (p Value)
(BMI, FLI) 1300/18 64.3 Reference Reference
(BMI, FLIþ) 10/1 0.5 – –
(BMIþ, FLI) 438/10 23.7 0.99 (0.42–2.28) 0.92
(BMIþ, FLIþ) 272/23 13.5 10.3 (5.69–18.4) <0.0001
B)
Frequency (n¼ 2020) Percent OR (95% CI) (p Value)
(BMI, FLI) 1703/27 84.3 Reference Reference
(BMI, FLIþ) 121/2 6.0 1.08 (0.25–4.76) .95
(BMIþ, FLI) 35/1 1.7 1.62 (0.21–12.4) .56
(BMIþ, FLIþ) 161/22 8.0 8.94 (4.86–16.5) <.0001
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used the FLI as a simple and accurate predictor of
hepatic steatosis in the general population. FLI was
originally developed using ultrasonography first sug-
gested by Bedogni et al. and we subsequently vali-
dated its utility in predicting the likelihood of NAFLD
in healthy controls and insulin-resistant individuals
with obesity using proton magnetic resonance spec-
troscopy (1H-MRS) [16,17]. The association of higher
FLI with type 2 diabetes has been noted in several
previous studies [25–27]. First, in the PREDAPS study,
examining a Spanish cohort of 1142 adults with pre-
diabetes, of whom 55.7% had hepatic steatosis (FLI >
60), FLI  60 was independently associated with type
2 diabetes incidence at 3 years of follow up, HR 4.97
(95% CI 2.28–10.8) and 3.21 (95% CI 1.45–7.09) in a
fully adjusted model [27]. Second, in another study of
1792 Finnish men examining the associations of fatty
liver with incident type 2 diabetes, there was a steady
increase in HR of incident type 2 diabetes across FLI
categories of 10, with every unit increase in FLI associ-
ated with 1.8% increase in HR. Compared with FLI of
 30, an FLI 30 60 was associated with HR of 1.79
(1.33, 2.37) and an FLI  60 with HR of 2.63 (1.89,
3.66) [25]. In a further study of 2784 Korean adults a
similar relationship was seen with FLI according to the
same groupings of FLI: 30, 30 60 or  60: odds
ratio for new-onset type 2 diabetes for FLI < 30 vs.
30–59 vs.  60 was 1.87 (1.05, 3.33) and 2.84 (1.4,
5.75) [26]. Interestingly a recent study demonstrated
that a change in NAFLD status over time, determined
by serial FLI and abdominal ultrasonography, influen-
ces the risk of incident type 2 diabetes: the risk with
resolved NAFLD was not significantly different from
that with no NAFLD [28].
This study attempts to gain further insight by
examining the synergistic risk between weight status
(overweight/obese) and presence/absence of NAFLD.
The findings we present concur with findings from a
large Korean population of 34,258 participants (with-
out type 2 diabetes) where the influence of NAFLD
(implied from a high FLI measurement) as a determin-
ant of incident type 2 diabetes was examined. The risk
of incident type 2 diabetes in individuals with obesity
who were MHO, with a low FLI, was not significantly
increased compared with the MHO non-obese; in con-
trast, individuals with obesity who were MUO, with a
high FLI, had an almost 2-fold risk of incident type 2
diabetes [29]. While MHO is associated with a lower
risk of incident type 2 diabetes compared with MUO
[30], a meta-analysis of all the studies examining dif-
ferent obesity phenotypes clearly indicate that
although being MHO confers some protection, all
adults with obesity show a substantially increased risk
of developing type 2 diabetes compared with MHO
normal-weight adults [15].
So why does NAFLD seem to be associated with
type 2 diabetes? Attempts to differentiate healthy and
unhealthy normal weight and obesity have focussed
on body fat distribution and ectopic fat deposition
but have highlighted that poor metabolic health,
regardless of weight, is characterized by higher liver
fat, higher visceral fat and insulin resistance [31]. The
mechanism behind this relationship between liver fat,
metabolic syndrome and type 2 diabetes was explored
in a study investigating the dose response between
liver fat and metabolic end points [32]. Once liver fat
accumulation exceeds 6 ± 2%, slightly exceeding the
upper limit of normal of liver fat in the general popu-
lation (5.56%) as defined in the Dallas Heart Study
[33], skeletal muscle insulin resistance, hypertriglyceri-
daemia and low HDL-cholesterol become evident. In
addition to steatosis, the association of liver fibrosis
with type 2 diabetes has been noted by others. In a
retrospective study of 396 patients with biopsy-proven
NAFLD, Bjorkstrom et al. found a higher proportion of
patients with fibrosis stages 3– develop type 2 dia-
betes than patients with fibrosis stages 0–2 while in
patients with fibrosis stages 0–2, fat score was associ-
ated with risk of type 2 diabetes [34].
The limitations of the study include the relatively
small number of participants who subsequently devel-
oped type 2 diabetes. We also acknowledge the limita-
tion of using a surrogate measure of NAFLD at
baseline, the FLI, with no abdominal ultrasonography
available although validations studies with ultrasound
and even proton-magnetic resonance spectroscopy
demonstrates its accuracy. Due to high multicollinear-
ity, results from the regression model including FLI
and any of its parameters together, should be inter-
preted cautiously.
In summary, we find that the degree of elevation of
the FLI significantly modulates the risk of incident pre-
diabetes or type 2 diabetes associated with being
overweight or obese.
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